Literature DB >> 20829741

Endogenous endophthalmitis associated with intravenous drug abuse: seven-year experience at a tertiary referral center.

Paul P Connell1, Evelyn C O'Neill, F M Amirul Islam, Robert Buttery, Mark McCombe, Rohan H Essex, Edward Roufail, Stephen Lash, Bernard Wolffe, Ben Clark, Daniel Chiu, William Campbell, Penelope Allen.   

Abstract

PURPOSE: Intravenous drug use (IVDU) is a known risk factor for endogenous endophthalmitis. Endogenous fungal endophthalmitis (EFE) is emerging as a common problem among this community. We describe the management and visual outcomes of acute IVDU-associated EFE.
METHODS: A prospective consecutive case series of 19 patients presenting with presumed acute IVDU-associated EFE from 2001 to 2007 to the Royal Victorian Eye and Ear Hospital was included. All data were collected in a standardized manner. Outcome measures included visual acuity, microbial profiles, and vitrectomy rate.
RESULTS: Nineteen cases of IVDU-associated EFE were identified. Eight of these (42%) were men, and the mean age was 32.7 years (SD ± 8.0 years). Presenting visual acuity ranged from 6/6 to perception of light, with 58% having a visual acuity of 6/48 or less at presentation. Thirteen (68.4%) were culture positive with all cultures identifying Candida species, and 52.7% underwent vitrectomy. Fifty percent of subjects overall achieved a final visual acuity of 6/18 or better. Men demonstrated improved visual acuity when compared with women (P = 0.04). Age had no effect on final acuity.
CONCLUSION: Intravenous drug use is a significant risk factor for developing EFE. Good visual outcomes can be achieved with early treatment, often with intravitreal therapy alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829741     DOI: 10.1097/IAE.0b013e3181dd6db6

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  59 eyes with endogenous endophthalmitis- causes, outcomes and mortality in a Danish population between 2000 and 2016.

Authors:  Søren Solborg Bjerrum; Morten la Cour
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-08       Impact factor: 3.117

2.  An Outbreak of Endogenous Fungal Endophthalmitis Among Intravenous Drug Abusers in New England.

Authors:  Aubrey R Tirpack; Jay S Duker; Caroline R Baumal
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

3.  Retinal neovascularization and endogenous fungal endophthalmitis in intravenous drug users.

Authors:  Thuy Doan; Gurunadh A Vemulakonda; Deana Choi; C Dirk Keene; Lakshmi Akileswaran; Russell N Van Gelder; Jennifer R Chao
Journal:  Ophthalmology       Date:  2014-05-23       Impact factor: 12.079

4.  Endophthalmitis: A review of recent trends.

Authors:  Janice R Safneck
Journal:  Saudi J Ophthalmol       Date:  2012-03-03

Review 5.  Endophthalmitis.

Authors:  M L Durand
Journal:  Clin Microbiol Infect       Date:  2013-03       Impact factor: 8.067

6.  Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections.

Authors:  Jayanth Sridhar; Harry W Flynn; Ajay E Kuriyan; Darlene Miller; Thomas Albini
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-09-20

7.  Intralesional antibiotic injection using 41G needle for the management of subretinal abscess in endogenous endophthalmitis.

Authors:  Pradeep Venkatesh; Shreys Temkar; Koushik Tripathy; Rohan Chawla
Journal:  Int J Retina Vitreous       Date:  2016-08-01

8.  Liver Abscess Combined with Endogenous Endophthalmitis Caused by Genotype ST25 Serotype K2 Hypervirulent Klebsiella pneumoniae: A Case Report.

Authors:  Jian Lin; Yize Huang; Li Qian; Xiaolong Pan; Youliang Song
Journal:  Infect Drug Resist       Date:  2022-08-17       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.